BS_GNV89A5P
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 105.84
- os_event
- false
- age_years
- 10.564
- sex
- F
- race
- White
- new_clusters
- C6
- umap1_2d
- 3.078132974
- umap2_2d
- 6.095253538
- umap1_3d
- 1.751977454
- umap2_3d
- -0.728538709
- umap3_3d
- -4.57740798
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- PROTEIN_SECRETION+0.470
- DNA_REPAIR+0.390
- G2M_CHECKPOINT+0.390
- MYC_TARGETS_V1+0.310
- OXIDATIVE_PHOSPHORYLATION+0.310
- MITOTIC_SPINDLE+0.240
- PI3K_AKT_MTOR_SIGNALING+0.190
- FATTY_ACID_METABOLISM+0.170
- WNT_BETA_CATENIN_SIGNALING+0.160
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- ALLOGRAFT_REJECTION-0.430
- INFLAMMATORY_RESPONSE-0.410
- KRAS_SIGNALING_DN-0.400
- INTERFERON_ALPHA_RESPONSE-0.390
- INTERFERON_GAMMA_RESPONSE-0.360
- TNFA_SIGNALING_VIA_NFKB-0.350
- IL2_STAT5_SIGNALING-0.340
- KRAS_SIGNALING_UP-0.340
- COAGULATION-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_4CP4T22V | Med | Medulloblastoma | 0.940 |
| 2 | MDT-AP-3307 | Med | Medulloblastoma | 0.903 |
| 3 | MDT-AP-0357 | Med | Medulloblastoma | 0.899 |
| 4 | MDT-AP-0156 | Med | Medulloblastoma | 0.894 |
| 5 | BS_HF3RNN2T | Med | Medulloblastoma | 0.894 |
| 6 | MDT-AP-3088 | Med | Medulloblastoma | 0.891 |
| 7 | MDT-AP-0113 | Med | Medulloblastoma | 0.887 |
| 8 | MDT-AP-0553 | Med | Medulloblastoma | 0.885 |
| 9 | BS_J8G4SH4Z | Med | Medulloblastoma | 0.884 |
| 10 | SRR23303743 | — | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.390 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.010 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |